News

The European Medicines Agency (EMA) recently reviewed products containing the antibiotics colistin or colistimethate sodium (known as polymyxins) and recommended alterations to product sheet information to include safety and the most updated information when applied to treating infections that demonstrated to be resistant to other standard antibiotics. This update…

Vertex Pharmaceuticals‘ Ivacaftor (Kalydeco), a breakthrough medication for the treatment of patients suffering from a specific gene mutation of cystic fibrosis, has been approved to be added to the list of the Pharmaceutical Benefits Scheme (PBS) in Australia, and will become available on December 1st, as announced by Australian…

An Optical Society release notes that while people might typically regard mucus as an “icky bodily secretion best left wrapped in a tissue,” for a group of researchers from the University of North Carolina at Chapel Hill, “snot is an endlessly fascinating subject.” The team has developed a way to use…

A new study on the effect of female hormones in pulmonary exacerbations in cystic fibrosis patients, entitled “Subcutaneous implant with etonogestrel (Implanon®) for catamenial exacerbations in a patient with cystic fibrosis: a case report” and published in the journal BMC Pulmonary Medicine by Dr. Adelaida Lamas,…

Advocates and fundraisers for Cystic Fibrosis continue to develop creative, unique ways to increase awareness of the disease throughout the world and support ongoing clinical research for effective, new therapeutic strategies. Recently, the Cystic Fibrosis Association of New Zealand (CFNZ) joined forces with Ballentynes Fashion Central to organize a fundraising fashion show…

A novel Cystic Fibrosis testing technology that features next-generation DNA sequencing platforms has been launched by Medical Diagnostic Laboratories, L.L.C. Certified by the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), MDL specializes in complex, state-of-the-art, automated DNA-based molecular analyses. The MDL Cystic Fibrosis Core Test is a CFTR gene sequence exam provided…

A new study from Karolinska Institute entitled “Interleukin-26 in Antibacterial Host Defense of Human Lungs: Effects on Neutrophil Mobilization” and published in the American Journal of Respiratory and Critical Care Medicine describes a new mechanism of antibacterial defense in the lungs, mediated by…

Vertex Pharmaceuticals Incorporated announced Tuesday that the U.S. Food and Drug Administration’s Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of Kalydeco (ivacaftor) in people with cystic fibrosis (CF) ages six and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene,…

Specialty drug discovery company Proteostasis Therapeutics, Inc. has officially welcomed 6 new members to its clinical advisory board, who will have a direct impact on the company’s efforts in developing therapies for cystic fibrosis. The company is internationally known for its focus on developing cutting edge treatments for…

A new study on chronic lung infections associated with cystic fibrosis (CF) entitled “Polymorphonuclear Leukocytes Restrict Growth of Pseudomonas aeruginosa in the Lungs of Cystic Fibrosis Patients” recently published in the Infection and Immunity journal, is shedding new light on bacterial behavior in lung…